Klaus Frueh, Ph.D.(left), Scott Hansen, Ph.D., and colleagues at the OHSU Vaccine and Gene Therapy Institute lead the development of a cytomegalovirus-based vaccine platform that is now being tested to stop HIV in people. After 20 years of development, the experimental vaccine’s OHSU development team have published research that explains the unique biological mechanisms that make the technology work. (OHSU/Kristyna Wentz-Graff)
